31 August 2022FeaturesJurisdiction reportsKate Legge and Emily Dwyer

Australia: Regulatory exclusivities for pharmaceuticals

The Australian exclusivity regime for medicines differs from those in place in the northern hemisphere. It also contains subtleties that sponsors (originator and generic/biosimilars) need to know to determine the impact on generic/biosimilar market formation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Australia extends EPO fast-track patent examinations

21 June 2022 Australia’s IP office, IP Australia, and the European Patent Office (EPO) have agreed to continue the patent prosecution highway (PPH) programme, following a successful pilot phase.

Patents

Australia reverses DABUS AI inventorship ruling

13 April 2022 The Federal Court of Australia has overturned its prior ruling that artificial intelligence (AI) can be a named inventor on a patent application, striking down the last year’s surprising win for Stephen Thaler and his ongoing AI inventorship campaign.

Huawei wins seven-country ban on Netgear routers at the UPC

Lenovo faces US import ban as ITC sides with Ericsson

Arusha Protocol takes root: Fresh growth for plant variety protection in Africa

‘The politics of AI are developing’: Will Trump give tech a free ride?

‘AI curious’ counsel at AZ, Novartis and Orange weigh risks and benefits

China: Unpacking the first successful patent invalidation due to unauthorised foreign filing

SharkNinja overturns Dyson’s vacuum ban at the UPC

On our radar… Smashburger, OpenAI, Feminist Cyberlaw

Australia: Regulatory exclusivities for pharmaceuticals

More on this story

Editor's picks

Editor's picks

More articles